ALP - PORTAGE BIOTECH INC.

0.183
-0.047   -25.683%

Share volume: 15,484,001
Last Updated: 04-23-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$0.23
-0.05
-0.20%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
-42.81%
1 Month
-46.71%
3 Months
-70.93%
6 Months
-96.43%
1 Year
-98.03%
2 Year
-26.86%
Key data
Stock price
$0.18
P/E Ratio 
0.00
DAY RANGE
$0.18 - $0.21
EPS 
N/A
52 WEEK RANGE
$0.18 - $13.80
52 WEEK CHANGE
-$97.83
MARKET CAP 
3.618 M
YIELD 
N/A
SHARES OUTSTANDING 
1.049 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
1.56
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$31,625,381
AVERAGE 30 VOLUME 
$12,616,203
Company detail
CEO: Ian B. Walters
Region: US
Website: portagebiotech.com
Employees: 6
IPO year: 2007
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Portage Biotech Inc. researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology.

Recent news